Britany Helton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Britany Helton has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Andreas M. Kogelnik
ProDx Health, Menlo Park, CA 94025, USA
1 shared publication - Anindita Issa
National Center for Emerging and Zoonotic Infections, Centers for Disease Control and Prevention, Atlanta, USA
1 shared publication - Benjamin H. Natelson
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication - Carl Gunnar Gottschalk
Research and Development Lab, Simmaron Research Inc., University of Wisconsin-Milwaukee, Milwaukee, USA
1 shared publication - Catrina C. Phan
Open Medicine Clinic, Mountain View, CA 94040, USA
1 shared publication - Charles W. Lapp
Hunter-Hopkins Center, Charlotte, NC 28226, USA
1 shared publication
Latest Publications
- Open Access
- 28 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1369
Heterogeneity in Measures of Illness among Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Not Explained by Clinical Practice: A Study in Seven U.S. Specialty Clinics
Background: One of the goals of the Multi-site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM) study was to evaluate whether clinicians experienced in diagnosing and caring for patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) recognized the same clinical entity. Methods: We enrolled participants from seven specialty clinics in the United States. We used baseline data (n = 465) on standardized questions measuring general clinical characteristics, functional impairment, post-exertional malaise, fatigue, sleep, neurocognitive/autonomic symptoms, pain, and other symptoms to evaluate whether patient characteristics differed by clinic. Results: We found few statistically significant and no clinically significant differences between clinics in their patients’ standardized measures of ME/CFS symptoms and function. Strikingly, patients in each clinic sample and overall showed a wide distribution in all scores and measures. Conclusions: Illness heterogeneity may be an inherent feature of ME/CFS. Presenting research data in scatter plots or histograms will help clarify the challenge. Relying on case–control study designs without subgrouping or stratification of ME/CFS illness characteristics may limit the reproducibility of research findings and could obscure underlying mechanisms.
- 28 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1369
Open AccessHeterogeneity in Measures of Illness among Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Is Not Explained by Clinical Practice: A Study in Seven U.S. Specialty Clinics
Background: One of the goals of the Multi-site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM) study was to evaluate whether clinicians experienced in diagnosing and caring for patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) recognized the same clinical entity. Methods: We enrolled participants from seven specialty clinics in the United States. We used baseline data (n = 465) on standardized questions measuring general clinical characteristics, functional impairment, post-exertional malaise, fatigue, sleep, neurocognitive/autonomic symptoms, pain, and other symptoms to evaluate whether patient characteristics differed by clinic. Results: We found few statistically significant and no clinically significant differences between clinics in their patients’ standardized measures of ME/CFS symptoms and function. Strikingly, patients in each clinic sample and overall showed a wide distribution in all scores and measures. Conclusions: Illness heterogeneity may be an inherent feature of ME/CFS. Presenting research data in scatter plots or histograms will help clarify the challenge. Relying on case–control study designs without subgrouping or stratification of ME/CFS illness characteristics may limit the reproducibility of research findings and could obscure underlying mechanisms.